Nateglinide

An oral antidiabetic medication

Nateglinide
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Nateglinide is an oral antidiabetic drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as meglitinides, which stimulate the pancreas to release insulin.

Mechanism of Action

Nateglinide works by closing the ATP-sensitive potassium channels in the beta cells of the pancreas. This action leads to the opening of calcium channels, resulting in an influx of calcium ions and subsequent release of insulin. The drug is particularly effective in controlling postprandial blood glucose levels.

Pharmacokinetics

Nateglinide is rapidly absorbed from the gastrointestinal tract and has a quick onset of action. It is metabolized primarily in the liver by the cytochrome P450 enzyme system, particularly CYP2C9 and CYP3A4. The drug has a short half-life, which minimizes the risk of hypoglycemia.

Clinical Use

Nateglinide is indicated for the treatment of type 2 diabetes mellitus in conjunction with diet and exercise. It is often used in combination with other antidiabetic agents such as metformin or thiazolidinediones.

Side Effects

Common side effects of nateglinide include:

• Hypoglycemia
• Upper respiratory tract infection
• Dizziness
• Joint pain

Contraindications

Nateglinide is contraindicated in patients with:

• Type 1 diabetes mellitus
• Diabetic ketoacidosis
• Known hypersensitivity to the drug

Administration

Nateglinide is administered orally, typically taken before meals to optimize its effect on postprandial glucose levels.

Related pages

• Type 2 diabetes mellitus
• Insulin
• Meglitinides
• Hypoglycemia

• 

  Nateglinide